Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.

Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva A, Milota T, Faust SN, Williams AP, Hayman G, Kucuk ZY, Hague R, French P, Brooker R, Forsyth P, Herriot R, Cancrini C, Palma P, Ariganello P, Conlon N, Feighery C, Gavin PJ, Jones A, Imai K, Ibrahim MA, Markelj G, Abinun M, Rieux-Laucat F, Latour S, Pellier I, Fischer A, Touzot F, Casanova JL, Durandy A, Burns SO, Savic S, Kumararatne DS, Moshous D, Kracker S, Vanhaesebroeck B, Okkenhaug K, Picard C, Nejentsev S, Condliffe AM, Cant AJ. · 2017

Read Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. by Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva A, Milota T, Faust SN, Williams AP, Hayman G, Kucuk ZY, Hague R, French P, Brooker R, Forsyth P, Herriot R, Cancrini C, Palma P, Ariganello P, Conlon N, Feighery C, Gavin PJ, Jones A, Imai K, Ibrahim MA, Markelj G, Abinun M, Rieux-Laucat F, Latour S, Pellier I, Fischer A, Touzot F, Casanova JL, Durandy A, Burns SO, Savic S, Kumararatne DS, Moshous D, Kracker S, Vanhaesebroeck B, Okkenhaug K, Picard C, Nejentsev S, Condliffe AM, Cant AJ. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5292996.txt.

Introduction

Tanya I. Coulter and many colleagues described the clinical spectrum of activated PI3K-delta syndrome in the Journal of Allergy and Clinical Immunology in 2017. The syndrome is an inherited immunodeficiency caused by overactive versions of the PI3K-delta enzyme. The team gathered questionnaires, case notes, scans, tissue results, and lab data on 53 confirmed patients worldwide.

Nearly all, 98 percent, suffered repeated chest and sinus infections, and three quarters had non-cancerous lymph overgrowth, often from childhood. Herpesvirus infections hit 49 percent, autoinflammatory disease 34 percent, and lymphoma 13 percent. A surprise was developmental delay in 19 percent, and the enzyme is active in the developing mouse brain. Chest scans showed patchy air trapping in 90 percent and bronchiectasis in 60 percent. Lab hallmarks included high IgM and low CD4 counts, though none predicted severity, which ran from silent to fatal in early childhood. Five patients died; five received stem cell transplants.

Catalog record

CREATORCoulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, Goodlad JR, Farmer G, Steele CL, Leahy TR, Doffinger R, Baxendale H, Bernatoniene J, Edgar JD, Longhurst HJ, Ehl S, Speckmann C, Grimbacher B, Sediva A, Milota T, Faust SN, Williams AP, Hayman G, Kucuk ZY, Hague R, French P, Brooker R, Forsyth P, Herriot R, Cancrini C, Palma P, Ariganello P, Conlon N, Feighery C, Gavin PJ, Jones A, Imai K, Ibrahim MA, Markelj G, Abinun M, Rieux-Laucat F, Latour S, Pellier I, Fischer A, Touzot F, Casanova JL, Durandy A, Burns SO, Savic S, Kumararatne DS, Moshous D, Kracker S, Vanhaesebroeck B, Okkenhaug K, Picard C, Nejentsev S, Condliffe AM, Cant AJ.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5292996

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study By Tanya I Coulter, Anita Chandra, Chris M Bacon, Judith Babar, James Curtis, Nick Screaton, John R Goodlad, George Farmer, Cathal Laurence Steele, Timothy Ronan Leahy, Rainer Doffinger, Helen Baxendale Published in: The Journal of Allergy and Clinical Immunology DOI: 10.1016/j.jaci.2016.06.021 ABSTRACT Abstract Background Activated phosphoinositide 3-kinase δ syndrome (APDS) is a recently described combined immunodeficiency resulting from gain-of-function mutations in PIK3CD, the gene encoding the catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ). Objective We sought to review the clinical, immunologic, histopathologic, and radiologic features of APDS in a large genetically defined international cohort. Methods We applied a clinical questionnaire and performed review of medical notes, radiology, histopathology, and laboratory investigations of 53 patients with APDS. Results Recurrent sinopulmonary infections (98%) and nonneoplastic lymphoproliferation (75%) were common, often from childhood. Other significant complications included herpesvirus infections (49%), autoinflammatory disease (34%), and lymphoma (13%). Unexpectedly, neurodevelopmental delay occurred in 19% of the cohort, suggesting a role for PI3Kδ in the central nervous system; consistent with this, PI3Kδ is broadly expressed in the developing murine central nervous system. Thoracic imaging revealed high rates of mosaic attenuation (90%) and bronchiectasis (60%). Increased IgM levels (78%), IgG deficiency (43%), and CD4 lymphopenia (84%) were significant immunologic features. No immunologic marker reliably predicted clinical severity, which ranged from asymptomatic to death in early childhood. The majority of patients received immunoglobulin replacement and antibiotic prophylaxis, and 5 patients underwent hematopoietic stem cell transplantation. Five patients died from complications of APDS. Conclusion APDS is a combined immunodeficiency with multiple clinical manifestations, many with incomplete penetrance and others with variable expressivity. The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease. Clinical trials of selective PI3Kδ inhibitors offer new prospects for APDS treatment. Key words: Activated phosphoinositide 3-kinase δ syndrome; p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency; phosphoinositide 3-kinase δ; PIK3CD gene; bronchiectasis; immunodeficiency; hematopoietic stem cell transplantation; phosphoinositide 3-kinase inhibitor Abbreviations used: APDS, Activated phosphoinositide-3 kinase δ syndrome; BALF, Bronchoalveolar lavage fluid; CMV, Cytomegalovirus; CNS, Central nervous system; CT, Computed tomography; GOF, Gain of function; HSCT, Hematopoietic stem cell transplantation; HSV, Herpes simplex virus; OR, Odds ratio; PI3K, Phosphoinositide 3-kinase; PPV, Pneumococcal polysaccharide vaccine Discuss this article on the JACI Journal Club blog: www.jaci-online.blogspot.com. Activated phosphoinositide 3-kinase δ syndrome (APDS) is an autosomal dominant primary immunodeficiency caused by gain-of-function (GOF) mutations in PIK3CD,1, 2 which encodes the p110δ catalytic subunit of phosphoinositide 3-kinase δ (PI3Kδ). PI3Kδ, a class 1 PI3K isoform generating phosphatidylinositol 3,4,5-trisphosphate, is a heterodimer comprising p110δ and a p85 family regulatory subunit. PI3Kδ is expressed predominantly in leukocytes and plays an important role in their proliferation, survival, and activation.3, 4, 5 Recently, we described 17 patients with a combined immunodeficiency disorder caused by the heterozygous PIK3CD GOF mutation E1021K.1 Patients' lymphocytes displayed increased basal and poststimulation phosphatidylinositol 3,4,5-trisphosphate and enhanced downstream Akt–mammalian/mechanistic target of rapamycin signaling. This disorder was named APDS.1 Lucas et al2 independently reported 14 patients with a similar disease caused by E1021K and 2 other activating mutations in PIK3CD, designating it p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI).2 To date, 4 heterozygous GOF PIK3CD mutations (E1021K, N334K, E525K, and C416R) have been described, with E1021K the most common.1, 2, 6, 7, 8 Patients in both cohorts experienced recurrent respiratory tract infections, bronchiectasis, herpesvirus infections, nonneoplastic lymphoproliferation, and lymphoma. However, possibly because of different case-finding strategies, we reported bronchiectasis in 75% of our cohort and herpesvirus infections in 24%, whereas Lucas et al2 described bronchiectasis in 33%, but all patients had herpesvirus viremia. Recent reports have also underscored that patients with APDS have a high incidence of lymphoma7, 8 and possible autoimmune manifestations.2, 9 In this study we describe the clinical, radiologic, histopathologic, and immunologic features of APDS in a genetically confirmed cohort of 53 patients, the largest to date. We demonstrated a wide spectrum of clinical findings and complications and unexpectedly noted an increased frequency of neurodevelopmental manifestations. These findings will aid clinical decision making in the diagnosis and treatment of APDS and facilitate patient counseling. METHODS Informed consent was obtained from patients, parents, or both. The study conformed to the Declaration of Helsinki and all local ethical requirements. Mutations in PIK3CD were identified by means of Sanger sequencing.1 Only patients heterozygous for an APDS-associated GOF PIK3CD mutation were included. Twenty-five patients from this cohort have been included in previous reports,1, 7 and 28 are reported for the first time. Information on demographics, presentation, complications, laboratory parameters, management, and outcomes was compiled retrospectively by using patient/parent interview and medical note review. Pneumonia and bronchiectasis required radiologic confirmation. Chest computed tomographic (CT) scans from 31 patients were independently reviewed by 2 thoracic radiologists (J.B. and N.S.) for air-space opacity, atelectasis, nodules, bronchiectasis, mosaic attenuation, and lymphadenopathy.10, 11 Available histopathology specimens (29 specimens from 11 patients) were reviewed by 2 hematopathologists (C.M.B. and J.R.G.). Patients’ most recent immunology results are described; postrituximab B-cell levels were excluded. All laboratory results were analyzed with reference to age-related normal ranges.12, 13, 14, 15 A poor pneumococcal polysaccharide vaccine (PPV) response was defined as a less than 4-fold increase in antipneumococcal IgG titer at 4 to 6 weeks after PPV vaccination. Significant associations in clinical complications were determined by odds ratios (ORs) with 95% CIs and Fisher exact tests by using GraphPad Prism software (version 6; GraphPad Software, La Jolla, Calif). P values of less than .05 were considered significant. RESULTS Patients' characteristics Fifty-three patients with APDS (34 male patients) from 30 unrelated families were included; 5 patients (4 male) were deceased. Living patients had a mean age of 17.2 years (age range, <1-65 years). Forty-two patients were of European descent, 4 were Afro-Caribbean, 3 were Middle Eastern, 2 were Indian, 1 was Chinese, and 1 was Japanese. Fifty patients were heterozygous for E1021K, and 3 related subjects were heterozygous for E525K. Presentation Recurrent respiratory tract infections occurred in 96% of patients, with onset from less than 1 to 7 years of age. Lymphadenopathy, hepatosplenomegaly, or both were common at presentation (42%). Five patients were identified in adulthood after their child received a diagnosis of APDS; 2 had bronchiectasis and recurrent respiratory tract infections, 1 experienced recurrent respiratory tract infections in childhood and a persistent granulomatous local skin reaction to BCG vaccination, 1 was under investigation for chronic cervical lymphadenopathy, and 1 had no reported health issues. The 4 symptomatic adults had abnormal immunoglobulin profiles, including increased IgM and reduced IgG2 levels, although none had a low total IgG level. Infective complications Pneumonia (85%), bronchiectasis (60%), and upper respiratory tract infections were common, often with childhood onset (Table I). Only 2 patients did not report recurrent respiratory tract infections. The most common bacterial pathogens were Streptococcus pneumoniae and Haemophilus influenzae, with Staphylococcus aureus, Moraxella catarrhalis, Pseudomonas aeruginosa, and Klebsiella species also observed. The mean age at diagnosis of bronchiectasis was 8.6 years (range, 1.3-36 years). Four patients had permanent hearing loss from recurrent otitis media. Non–respiratory tract bacterial infections included ocular infections (21%: conjunctivitis [n = 8], dacryocystitis [n = 3], and orbital cellulitis [n = 2]) and abscesses

Read the complete text